EL7.AI
StocksMediumUpdated•Originally published 26 October 2026•Updated 26 October 2026•
1 min read

Acumen Pharmaceuticals Reports $78.6M Cash and Sets November Date for Alzheimer's Trial Results

Key Facts

1Acumen Pharmaceuticals reported cash, cash equivalents, and marketable securities of $78.6 million as of September 30, 2026.
2The company expects to report topline results for its Phase 2 study of sabirnetug for early Alzheimer's disease in November 2026.
3Current financial resources are expected to support clinical and operational activities into early 2027.

Acumen Pharmaceuticals reported cash, cash equivalents, and marketable securities totaling $78.6 million as of September 30, 2026. According to a statement released via GlobeNewswire, the company expects its current financial resources to support clinical and operational activities into early 2027.

The company expects to report topline results for its Phase 2 study of sabirnetug, a treatment for early Alzheimer's disease, in November 2026. Shares of ABOS closed at $1.98 on October 23, 2026, having traded between a low of $1.9 and a high of $2.05 during that session.

Latest Updates · 1

  1. Notable·

    Update: The company reported a third-quarter net loss of $25.4 million, or $0.35 per share, for the period ending September 30, 2026. This performance beat analyst estimates by $0.02 per share.

Open on chart